translation agency

CDC HIV/AIDS/Viral Hepatitis/STD/TB Prevention News Update
RiboGene's PCP Drug Approaches Clinical Trials

June 13, 1995
Business Wire (06/12/95)

On Monday, RiboGene, Inc. announced that it will proceed with human clinical trials of RG-201, the company's leading anti- fungal compound for the treatment of Pneumocystis carinii pneumonia. PCP is one of the most common opportunistic infections to affect AIDS patients. The drug is the company's first clinical trial candidate under its partnership with the University of North Carolina (UNC), Pharmo-Eco Laboratories, and Dr. Richard Tidwell of UNC, who is a consultant to RiboGene.